Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials

By Boyle P.   Gould A.L.   Roehrborn C.G.  

Urology, Vol. 48, Iss. 3, 1996-09 ,pp. : 398-405

Elsevier

Access to resources Recommend Favorite

Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia

By Boyle P.   Robertson C.   Lowe F.   Roehrborn C.  

Urology, Vol. 55, Iss. 4, 2000-04 ,pp. : 533-539

Elsevier

Access to resources Recommend Favorite

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia

By Elhilali M.M.   Ramsey E.W.   Barkin J.   Casey R.W.   Boake R.C.   Beland G.   Fradet Y.   Trachtenberg J.   Orovan W.L.   Schick E.   Klotz L.H.  

Urology, Vol. 47, Iss. 3, 1996-03 ,pp. : 335-342

Elsevier

Access to resources Recommend Favorite

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

By Hillman A.L.   Schwartz J.S.   Willian M.K.   Peskin E.   Roehrborn C.G.   Oesterling J.E.   Mason M.F.   Maurath C.J.   Deverka P.A.   Padley R.J.  

Urology, Vol. 47, Iss. 2, 1996-02 ,pp. : 169-178

Elsevier

Access to resources Recommend Favorite

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia

By Lepor H.  

Urology, Vol. 45, Iss. 3, 1995-03 ,pp. : 406-413

Elsevier

Access to resources Recommend Favorite